{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 98,
  "pageCount": 120,
  "prevPage": 97,
  "nextPage": 99,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "Includes process flow, flow cytometry data, and scatter plot of TCR frequency.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/98",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-98",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.7,
        "y": 0.55
      },
      "kind": "chart",
      "text": "BNT122 induces CD8+ T cell Infiltrates in tumors",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "74a504fc-a77b-4ab9-91df-9de4925f9765",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.35,
        "y": 0.55
      },
      "kind": "chart",
      "text": "BNT122 induces CD8+ T cells in CPI-sensitive and CPI-insensitive tumor types",
      "attrs": null,
      "subkind": "scatter",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b6a43ab5-6a5d-42d8-b5b6-9604b9b9e178",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "diagram",
      "text": "Evaluation of BNT122 safety & feasibility with/without Tecentriq in > 10 indications",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b061e913-c6bc-42f7-b0c7-0b448c7beff9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "CPI, checkpoint inhibitor; PR, partial response; PD, progressive disease; SD, stable disease. 1. Sahin U, et al. Nature 2017; 547:222-226; BNT121 was a precursor to BNT122 and the iNeST collaboration with Genentech.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59a784e0-5d5e-45f3-a747-6e6a8e0fccac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.9,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "list",
      "text": "Data from Phase 1 trial in heavily pre-treated, PD-L1 low patients across multiple tumor types; Demonstrated ability to elicit significant T cell responses; Treatment-related adverse events were primarily transient; Initial signals of clinical activity observed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c3efb3ce-99d1-441d-b8ff-fa6e94d54637",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "iNeST | Autogene cevumeran (BNT122) Phase 1 as monotherapy and in combination with atezolizumab",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a4f6ceb3-0da3-475b-9f8c-15dfd0e17d68",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 120,
      "from": 91,
      "beatId": "bf198718-eb7f-470f-aca0-0f710fbb4f37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product Pipeline",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The presentation showcases BioNTech's product pipeline, including its oncology and infectious disease programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}